Lymphatic Disorders

Among our newest initiatives, Expanse is advancing a minimally invasive implantable system that modulates lymphatic transport using a novel mechanism. Target indications include primary and secondary lymphatic disorders affecting 250M+ patients globally. Animal feasibility has been demonstrated.

This is a first-of-its-kind approach to a set of conditions that currently have no device-based solutions. This program is in early-stage development and reflects our commitment to entering clinical spaces that others have not yet addressed.